Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNRX Quoin Pharmaceuticals

Not Yet Opened 01-20 16:00:00 EST

10.45

+0.18

+1.75%

盘后10.45

+0.000.00%

16:47 EST

High10.64	Low10.06	Vol22.51K
Open10.34	D1 Closing10.27	Amplitude5.65%
Mkt Cap8.77M	Tradable Cap7.28M	Total Shares838.98K
T/O233.60K	T/O Rate3.23%	Tradable Shares696.50K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNRX","market":"US","secType":"STK","nameCN":"Quoin Pharmaceuticals","latestPrice":10.45,"timestamp":1768942800000,"preClose":10.27,"halted":0,"volume":22508,"hourTrading":{"tag":"盘后","latestPrice":10.45,"preClose":10.45,"latestTime":"16:47 EST","volume":9,"amount":95.1,"timestamp":1768945645789,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01752677702044788,"floatShares":696500,"shares":838976,"eps":-28.386957,"marketStatus":"Not Yet Opened","change":0.18,"latestTime":"01-20 16:00:00 EST","open":10.34,"high":10.6399,"low":10.06,"amount":233602.24758,"amplitude":0.056465,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-28.386957,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768986000000},"marketStatusCode":0,"adr":0,"adrRate":35,"exchange":"NASDAQ","adjPreClose":10.27,"preHourTrading":{"tag":"盘前","latestPrice":11,"preClose":10.27,"latestTime":"09:14 EST","volume":850,"amount":9348.456400000001,"timestamp":1768918467384,"change":0.73,"changeRate":0.071081,"amplitude":0.150925},"postHourTrading":{"tag":"盘后","latestPrice":10.45,"preClose":10.45,"latestTime":"16:47 EST","volume":9,"amount":95.1,"timestamp":1768945645789,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.83358},"requestUrl":"/m/hq/s/QNRX","defaultTab":"news","newsList":[{"id":"2604115270","title":"Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application for QRX003 in Saudi Arabia","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115270","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115270?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:30","pubTimestamp":1768915828,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd. has filed an application for Breakthrough Medicine Designation with the Saudi Food and Drug Authority  for QRX003, its lead investigational topical product for the treatment of Netherton Syndrome. If the designation is granted, QRX003 could become the first approved treatment for Netherton Syndrome and may be available for sale and reimbursement in Saudi Arabia in the second half of 2026. QRX003 is currently being evaluated in two late-stage clinical trials, with enrollment expected to be completed in the first half of 2026 and top-line data anticipated in the second half of the year. Quoin also plans to submit a New Drug Application in the United States and other territories pending successful clinical outcomes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL3CK6Kt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014021.USD","BK4585","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","SG9999014005.SGD","SG9999014039.USD","SG9999014013.SGD","NDAQ","QNRX","BK4139","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2589781062","title":"ADRs Close Lower; Quoin Pharmaceuticals Ltd. Declines 36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589781062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589781062?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:30","pubTimestamp":1764970200,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed lower on Friday, as the S&P/BNY Mellon index of American depositary receipts declined 0.3% to 232.31.The European index dropped 0.5% to 204.74. The Asian index gained 0.4% to 310.61. The Latin American index fell 4.2% to 234.96, while the emerging-markets index was flat at 518.38.Quoin Pharmaceuticals Ltd., based in Israel, posted the largest decline, cratering 36% to $12.09, followed by shares of China's Adlai Nortye Ltd., which tumbled 16% to $1.01. Shares of China-based Akso Health Group tumbled 11% to $1.39.China's PomDoctor Ltd. was the biggest leader during the session, jumping 15% to $5.45, and Israel-based SaverOne 2014 Ltd. surged 13% to $1.07. Concord Medical Services Holdings Ltd., which is based in China, rounded out the top three leaders on Friday, with shares surging 13% to $3.99.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2589489208","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2589489208","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589489208?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:55","pubTimestamp":1764939318,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals  shares were 19% lower pre-bell Friday after a 6.1% increase in the previous session.Polyrizon  stock was down 17%, paring Thursday's rally.Domo  shares were 14% lower after the company reported late Thursday lower fiscal Q3 revenue.Parsons  stock was down 14% after a 1.9% gain in the previous session.Argan  shares were 11% lower, a day after the company posted lower fiscal Q3 revenue.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1559883803.SGD","BK4123","LU2065731478.USD","QNRX","PSN","BK4129","DOMO","BK4187","BK4023","BK4139","LU0566484027.USD","AGX","PLRZ"],"gpt_icon":1},{"id":"2584670874","title":"Quoin Pharmaceuticals Approves New Stock Option Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2584670874","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584670874?lang=en_us&edition=fundamental","pubTime":"2025-11-18 06:34","pubTimestamp":1763418874,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. On November 14, 2025, Quoin Pharmaceuticals‘ Board of Directors approved new award agreemen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-approves-new-stock-option-agreements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-approves-new-stock-option-agreements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2584167240","title":"Quoin Pharmaceuticals Unveils New Equity Incentive Plan for Executives and Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2584167240","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584167240?lang=en_us&edition=fundamental","pubTime":"2025-11-18 06:01","pubTimestamp":1763416895,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd. has approved new forms of stock option award agreements for directors and executive officers under its 2025 Equity Incentive Plan. The updated agreements allow options to be exercised through various payment methods, including cash, check, wire transfer, and cashless exercise mechanisms. In the event of termination, unvested awards will be forfeited immediately. Vested awards may be exercised for up to one year after death or disability, or up to three months after termination for reasons other than death, disability, or cause. All awards, whether vested or unvested, will be forfeited immediately upon termination for cause.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL8BpCPj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2582374169","title":"Quoin Pharmaceuticals Achieves Key Milestone in Rapamycin Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374169?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:37","pubTimestamp":1762954664,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an update. On November 11, 2025, Quoin Pharmaceuticals announced the successful achievement of targ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-achieves-key-milestone-in-rapamycin-delivery?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-achieves-key-milestone-in-rapamycin-delivery?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2582736485","title":"Quoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2582736485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582736485?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:31","pubTimestamp":1762867871,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd. has announced the successful achievement of target loading concentrations for its two proprietary topical rapamycin delivery technologies. The company has formulated a topical lotion with a 4% w/w rapamycin concentration and a dermal patch system with a 5% w/w concentration. These developments mark a significant milestone for Quoin's topical rapamycin programs. The company plans to begin manufacturing clinical trial and stability batches in the fourth quarter of 2025, with clinical testing set to commence in the first half of 2026. Initial clinical indications will include Microcystic Lymphatic Malformations and Venous Malformations, for which no FDA-approved treatments currently exist. The results have been announced by the company and clinical testing will be conducted in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL3QV5M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2581144092","title":"Quoin Pharmaceuticals Ltd reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581144092","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581144092?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:07","pubTimestamp":1762441625,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd reports results for the quarter ended September 30 - Earnings SummaryQuoin Pharmaceuticals Ltd QNRX.OQ reported a quarterly adjusted loss of $6.71 per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL8N3WI2JB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2581929096","title":"Quoin Pharmaceuticals reports Q3 EPS ($6.71) vs. ($16.29) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2581929096","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581929096?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:36","pubTimestamp":1762436163,"startTime":"0","endTime":"0","summary":"“The third quarter of 2025 has been a period of significant momentum and strategic advancement for Quoin Pharmaceuticals (QNRX),” said Dr. Michael ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-reports-q3-eps-6-71-vs-16-29-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-reports-q3-eps-6-71-vs-16-29-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX"],"gpt_icon":0},{"id":"2581096917","title":"Quoin Pharmaceuticals sees cash runway into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096917","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581096917?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:35","pubTimestamp":1762436138,"startTime":"0","endTime":"0","summary":"Quoin had approximately $5.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The Company believes that this,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-sees-cash-runway-into-2027-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-sees-cash-runway-into-2027-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2581096317","title":"Quoin Pharmaceuticals Q3 EPS $(6.71) Misses $(6.50) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096317","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581096317?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:34","pubTimestamp":1762436071,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(6.71) per share which missed the analyst consensus estimate of $(6.50) by 3.15 percent. This is a 59.21 percent increase over losses of $(16.45) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48684934/quoin-pharmaceuticals-q3-eps-6-71-misses-6-50-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"gpt_icon":0},{"id":"2581096365","title":"Press Release: Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096365","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581096365?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:30","pubTimestamp":1762435800,"startTime":"0","endTime":"0","summary":"-- Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D. -- Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations. -- Pediatric Netherton Clinical Program Expanded Based on Positive Long-Term Safety and Efficacy Data. -- QRX003 Pivotal Studies to Commence Enrollment in Q4 2025. Quoin continued to advance its lead clinical asset, QRX003, and recruitment into both pivotal trials for Netherton Syndrome will commence in Q4 this year. The Company also recently completed a private placement financing with the potential to raise up to $105.3 million in gross proceeds , received $3.3 million from the exercise of warrants issued in December 2024 and made the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","METHmain","ETH.USD.HKCC","QNRX"],"gpt_icon":0},{"id":"2580534447","title":"Quoin Pharmaceuticals Ltd  expected to post a loss of $4.98 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580534447","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580534447?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:51","pubTimestamp":1762267867,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd  expected to post a loss of $4.98 a share - Earnings Preview Quoin Pharmaceuticals Ltd QNRX.OQ, QNRX.O is expected to  show no change in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG256:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2579141614","title":"Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579141614","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579141614?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:30","pubTimestamp":1761827400,"startTime":"0","endTime":"0","summary":"ASHBURN, Va., Oct.  30, 2025  (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the \"Company\" or \"Quoin\"), a late clinical-stage specialty pharmaceutical company focused on rare and orpha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177386/0/en/Quoin-Pharmaceuticals-to-Provide-Corporate-Update-and-Announce-Third-Quarter-2025-Financial-Results-on-Thursday-November-6-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2579186662","title":"Analysts Are Bullish on Top Healthcare Stocks: Quoin Pharmaceuticals (QNRX), Fulcrum Therapeutics (FULC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2579186662","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579186662?lang=en_us&edition=fundamental","pubTime":"2025-10-30 00:30","pubTimestamp":1761755411,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Quoin Pharmaceuticals (QNRX – Research Report) and F...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-quoin-pharmaceuticals-qnrx-fulcrum-therapeutics-fulc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-quoin-pharmaceuticals-qnrx-fulcrum-therapeutics-fulc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSH","BK4137","BK4007","QNRX","XLV","LABU","LU0128526141.USD","BK4112","FULC","XBI","BK4585","HCSG","BK4588","BK4139","LU0029874061.USD","BK4581"],"gpt_icon":0},{"id":"2578214952","title":"Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2578214952","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578214952?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:30","pubTimestamp":1761654600,"startTime":"0","endTime":"0","summary":"Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Who","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/28/3175438/0/en/Quoin-Pharmaceuticals-Announces-Recruitment-of-Three-Additional-Patients-in-Investigator-Pediatric-Netherton-Syndrome-Study-and-Provides-Positive-9-month-Whole-Body-Data-Update-fro.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IGA","BK4139","QNRX"],"gpt_icon":0},{"id":"2578621443","title":"Quoin Pharmaceuticals’ QRX003 Lotion: A Promising Study for Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2578621443","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578621443?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:39","pubTimestamp":1761586747,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd (($QNRX)) announced an update on their ongoing clinical study. Quoin Pharmaceuticals Ltd is conducting a clinical study t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-qrx003-lotion-a-promising-study-for-netherton-syndrome?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-qrx003-lotion-a-promising-study-for-netherton-syndrome?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2577319056","title":"ADRs Close Lower; Quoin Pharmaceuticals Ltd. Declines 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577319056","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577319056?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:30","pubTimestamp":1761165000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed lower on Wednesday, as the S&P/BNY Mellon index of American depositary receipts declined 0.2% to 227.35.The European index gained 0.4% to 198.98. The Asian index fell 1.0% to 308.49. The Latin American index rose 0.9% to 215.15, while the emerging-markets index fell 0.9% to 513.39.Quoin Pharmaceuticals Ltd., based in Israel, posted the largest decline, plummeting 25% to $12.10, followed by shares of Denmark's Evaxion A/S, which plunged 17% to $5.44. Shares of Japan-based Lead Real Estate Co. Ltd. tumbled 14% to $1.35.United Kingdom's Adaptimmune Therapeutics PLC was the biggest leader during the session, soaring 49% to 7 cents, and China-based Lixiang Education Holding Co. Ltd. rocketed 24% to 45 cents. Embotelladora Andina S.A. , which is based in Chile, rounded out the top three leaders on Wednesday, with shares rising 7.9% to $19.88.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2577878953","title":"Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2577878953","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577878953?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:40","pubTimestamp":1761050433,"startTime":"0","endTime":"0","summary":"Oct 21 (Reuters) - Quoin Pharmaceuticals Ltd <2EB0y.F>::*QUOIN PHARMACEUTICALS ANNOUNCES U.S. FDA GRANTS ORPHAN DRUG DESIGNATION FOR QRX003 IN NETHERTON SYNDROME  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 21-OCT-202512:30:00.313 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nRSD5Yz3BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2577878199","title":"Quoin Pharmaceuticals announces FDA granted ODD to QRX003","url":"https://stock-news.laohu8.com/highlight/detail?id=2577878199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577878199?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:35","pubTimestamp":1761050122,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation, ODD, to its lead product can...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-granted-odd-to-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-granted-odd-to-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139","BK4183","IE0009354923.USD","ODD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quoinpharma.com","stockEarnings":[{"period":"1week","weight":-0.0422},{"period":"1month","weight":-0.2641},{"period":"3month","weight":-0.1364},{"period":"6month","weight":0.2215},{"period":"1year","weight":-0.4773},{"period":"ytd","weight":-0.2758}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.219287},{"month":2,"riseRate":0,"avgChangeRate":-0.289248},{"month":3,"riseRate":0.25,"avgChangeRate":-0.225189},{"month":4,"riseRate":0.25,"avgChangeRate":-0.184354},{"month":5,"riseRate":0.5,"avgChangeRate":0.000391},{"month":6,"riseRate":0.5,"avgChangeRate":-0.071654},{"month":7,"riseRate":0.5,"avgChangeRate":-0.033987},{"month":8,"riseRate":0.5,"avgChangeRate":-0.098098},{"month":9,"riseRate":0,"avgChangeRate":-0.208503},{"month":10,"riseRate":0.5,"avgChangeRate":0.22434},{"month":11,"riseRate":0.4,"avgChangeRate":0.035616},{"month":12,"riseRate":0.2,"avgChangeRate":-0.187047}],"exchange":"NASDAQ","name":"Quoin Pharmaceuticals","nameEN":"Quoin Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quoin Pharmaceuticals,QNRX,Quoin Pharmaceuticals股票,Quoin Pharmaceuticals股票老虎,Quoin Pharmaceuticals股票老虎国际,Quoin Pharmaceuticals行情,Quoin Pharmaceuticals股票行情,Quoin Pharmaceuticals股价,Quoin Pharmaceuticals股市,Quoin Pharmaceuticals股票价格,Quoin Pharmaceuticals股票交易,Quoin Pharmaceuticals股票购买,Quoin Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction